

10/634,419

10

PC25286A

REMARKS

Claims 1 and 7 to 13 are pending in the application.

Claims 1 is currently amended.

Claims 7 to 9, 11, and 13 were previously presented.

Claims 2 to 6 are canceled.

Amendments to the Claim(s)

Claim 1 is amended to delete the definitions of the groups L, R⁵, R⁶, C₈-C₁₀ bicycloalkyl, and 8- to 10-membered heterobicycloalkyl, which became unnecessary when the definition of groups R¹ and Q were amended in Applicants' previous paper.

Claim Rejections – 35 USC § 112

In the Office Action, claims 1, 10, and 12 are rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It was argued that variable group L in claim 1 renders claim 1 and its dependent claims 10 and 12 unclear because claim 1 appears to have no variable L.

Applicants traverse the rejection because claim 1 is now amended to delete group L. Accordingly, Applicants believe that claim 1 and dependent claims 10 and 12 are definite and patentable under 35 U.S.C. § 112, second paragraph.

Allowable Subject Matter

Applicants note that claims 7 to 9 and 11 to 13 are allowed.

Conclusion

In view of the above amendment and remarks, Applicants believe that the rejection is overcome and request reconsideration of claims 1, 10, and 12.

10/634,419

11

PC25286A

Respectfully submitted,

Date: April 20, 2006

Claude F. Purchase

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553